Background: Cyst infection is a frequent and serious complication of autosomal dominant polycystic kidney disease (ADPKD) that is often difficult to treat. However, the factors influencing cyst infection are still unknown. Therefore, we investigated clinical factors related to the duration of hospitalization and death due to cyst infection. Methods: All ADPKD patients undergoing cyst drainage or nephrectomy or partial hepatectomy at Toranomon Hospital from January 2004 to March 2016, in whom cyst fluid analysis showed bacteria or neutrophils indicating definite cyst infection, were reviewed retrospectively. Factors influencing the duration of hospitalization and death due to cyst infection were analyzed. Results: A total of 243 patients with cyst infection were enrolled, including 104 men and 139 women (mean age: 62.6 ± 10.0 years). Seventeen patients died of cyst infection. Multivariate logistic regression analysis revealed that hepatomegaly, positive cyst contents culture, and the maximum white blood cell (WBC) count were significantly associated with death from cyst infection. Death was significantly more likely if patients had massive hepatomegaly (≥5,113.2 mL) compared with mild hepatomegaly (< 1,898.7 mL; odds ratio 38.1; 95% CI 2.9–492.6, p = 0.0004). Multivariate Cox proportional hazards analysis revealed that older age, dialysis duration, hepatic transcatheter arterial embolization, maximum WBC count, and hepatomegaly were significantly associated with longer hospital stay for cyst infection, while female sex, nephrectomy, serum albumin, and serum cholinesterase were significantly associated with shorter hospital stay. Discharge alive from hospital was significantly associated with massive hepatomegaly versus mild hepatomegaly (hazard ratio 0.0072; 95% CI 0.0008–0.0659, p < 0.0001). Conclusions: Hepatomegaly was strongly associated with both death and longer hospital stay due to cyst infection.

Keywords:
Autosomal dominant polycystic kidney disease, Cyst infection, Infected cyst, Polycystic kidney disease
1.
Torres VE: Polycystic Kidney Disease Autosomal-Dominant and Recessive Forms. Philadelphia, Lippincott Williams & Wilkins, 2001.
2.
Gardner KD Jr, Evan AP: Cystic kidneys: an enigma evolves. Am J Kidney Dis 1984; 3: 403–413.
3.
Schwab SJ, Bander SJ, Klahr S: Renal infection in autosomal dominant polycystic kidney disease. Am J Med 1987; 82: 714–718.
4.
Sallée M, Rafat C, Zahar JR, Paulmier B, Grünfeld JP, Knebelmann B, Fakhouri F: Cyst infections in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1183–1189.
5.
Suwabe T, Araoka H, Ubara Y, Kikuchi K, Hazue R, Mise K, Hamanoue S, Ueno T, Sumida K, Hayami N, Hoshino J, Imafuku A, Kawada M, Hiramatsu R, Hasegawa E, Sawa N, Takaichi K: Cyst infection in autosomal dominant polycystic kidney disease: causative microorganisms and susceptibility to lipid-soluble antibiotics. Eur J Clin Microbiol Infect Dis 2015; 34: 1369–1379.
6.
Harris PC, Torres VE: Polycystic kidney disease, autosomal dominant; in Adam MP (ed): GeneReviews®. Seattle, University of Washington, 2015.
7.
Chapman AB, Devuyst O, Eckardt KU, -Gansevoort RT, Harris T, Horie S, Kasiske BL, Odland D, Pei Y, Perrone RD, -Pirson Y, Schrier RW, Torra R, Torres VE, Watnick T, Wheeler DC; Conference Participants: Autosomal-dominant polycystic kidney disease (ADPKD): executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 2015; 88: 17–27.
8.
Lantinga MA, Casteleijn NF, Geudens A, de Sévaux RG, van Assen S, Leliveld AM, Gansevoort RT, Drenth JP; DIPAK Consortium: Management of renal cyst infection in patients with autosomal dominant polycystic kidney disease: a systematic review. Nephrol Dial Transplant 2017; 32: 144–150.
9.
Suwabe T, Ubara Y, Higa Y, Nakanishi S, Sogawa Y, Nomura K, Nishimura H, Hoshino J, Sawa N, Katori H, Takemoto F, Nakamura M, Tomikawa S, Hara S, Takaichi K: Infected hepatic and renal cysts: differential impact on outcome in autosomal dominant polycystic kidney disease. Nephron Clin Pract 2009; 112:c157–c163.
10.
Suwabe T, Ubara Y, Sumida K, Hayami N, Hiramatsu R, Yamanouchi M, Hasegawa E, Hoshino J, Sawa N, Saitoh S, Okuda I, Takaichi K: Clinical features of cyst infection and hemorrhage in ADPKD: new diagnostic criteria. Clin Exp Nephrol 2012; 16: 892–902.
11.
Suwabe, T, Ubara, Y, Mise, K, Ueno, T, Sumida, K, Yamanouchi, M, Hayami, N, Hoshino, J, Kawada, M, Imafuku, A, Hiramatsu, R, Hasegawa, E, Sawa, N, Takaichi, K: Suitability of patients with autosomal dominant polycystic kidney disease for renal transcatheter arterial embolization. J Am Soc Nephrol 2016; 27: 2177–2187.
12.
Hoshino J, Ubara Y, Suwabe T, Sumida K, Hayami N, Mise K, Hiramatsu R, Hasegawa E, Yamanouchi M, Sawa N, Takei R, Takaichi K: Intravascular embolization therapy in patients with enlarged polycystic liver. Am J Kidney Dis 2014; 63: 937–944.
13.
Aussilhou B, Douflé G, Hubert C, Francoz C, Paugam C, Paradis V, Farges O, Vilgrain V, Durand F, Belghiti J: Extended liver resection for polycystic liver disease can challenge liver transplantation. Ann Surg 2010; 252: 735–743.
14.
Chandok N, Uhanova J, Marotta P: Clinical outcomes of liver transplantation for polycystic liver disease: a single center experience. Ann Hepatol 2010; 9: 278–281.
15.
van Keimpema L, Drenth JP: Polycystic liver disease: a critical appraisal of hepatic resection, cyst fenestration, and liver transplantation. Ann Surg 2011; 253: 419.
16.
van Keimpema L, Nevens F, Adam R, Porte RJ, Fikatas P, Becker T, Kirkegaard P, Metselaar HJ, Drenth JP; European Liver and Intestine Transplant Association: Excellent survival after liver transplantation for isolated polycystic liver disease: an European Liver Transplant Registry study. Transpl Int 2011; 24: 1239–1245.
17.
Lanktree MB, Chapman AB: New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol 2017; 13: 750–768.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.